Keywords
Prostatic urethral dilation
LUTS
Minimally invasive therapy
Submitted : 2026-06-07
Accepted : 2026-06-22
Published : 2026-07-07
Abstract
Background: Small-volume benign prostatic obstruction (BPO) represents a distinct clinical phenotype in which lower urinary tract symptoms (LUTS) are often driven by functional and microenvironmental factors rather than anatomical enlargement. Conventional treatment strategies may be less effective in this subgroup. Case presentation: We report the case of a 66-year-old male with severe LUTS and a small prostate volume (20 mL) who showed inadequate response to medical therapy. The patient underwent prostatic urethral dilation (PUD) using an ultra-minimally invasive prostate dilation catheter (Longevity bar). At 3-month follow-up, improvements were observed in symptom score, urinary flow rate, and post-void residual volume, while sexual function was preserved, and no procedure-related complications occurred. Conclusion: PUD may provide a potential treatment option for selected patients with small-volume BPO. Further studies are needed to determine its long-term efficacy and clinical role.
References
Roehrborn C, 2005, Benign Prostatic Hyperplasia: An Overview. Reviews in Urology, 7(Suppl 9): S3–S14.
Miernik A, Gratzke C, 2020, Current Treatment for Benign Prostatic Hyperplasia. Deutsches Ärzteblatt International, 117(49): 843–854.
Lerner L B, McVary K, Barry M, et al., 2021, Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Part I—Initial Work-Up and Medical Management. Journal of Urology, 206(4): 806–817.
Xu J, Han B, Xia S, et al., 2025, Beyond Size: A Comprehensive Overview of Small-Volume Benign Prostatic Hyperplasia. Current Urology, 19(1): 1–5.
De Nunzio C, Presicce F, Tubaro A, 2016, Inflammatory Mediators in the Development and Progression of Benign Prostatic Hyperplasia. Nature Reviews Urology, 13(10): 613–626.
Fibbi B, Penna G, Morelli A, et al., 2010, Chronic Inflammation in the Pathogenesis of Benign Prostatic Hyperplasia. International Journal of Andrology, 33(3): 475–488.
Bushman W, Jerde T, 2016, The Role of Prostate Inflammation and Fibrosis in Lower Urinary Tract Symptoms. American Journal of Physiology-Renal Physiology, 311(4): F817–F821.
Savvides E, Langas G, Sountoulides P, 2024, Editorial for Special Issue: Current and Emerging Therapies for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. Journal of Clinical Medicine, 13(9): 2453.
Franco J, Tesolin P, Jung J, 2023, Update on the Management of Benign Prostatic Hyperplasia and the Role of Minimally Invasive Procedures. Prostate International, 11(1): 1–7.
Shen K, Chen C, Yu L, 2025, Dilemmas and Breakthroughs in the Treatment of Benign Prostatic Hyperplasia in China. Modern Health Science, 8(1): 112.
Yoosuf B, Panda A, Kt M, et al., 2024, Comparative Efficacy and Safety of Alpha-Blockers as Monotherapy for Benign Prostatic Hyperplasia: A Systematic Review and Network Meta-Analysis. Scientific Reports, 14(1): 11116.
Plochocki A, King B, 2022, Medical Treatment of Benign Prostatic Hyperplasia. Urologic Clinics of North America, 49(2): 231–238.
Couteau N, Duquesne I, Frédéric P, et al., 2021, Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review. Journal of Clinical Medicine, 10(24): 5788.
Elterman D, Aubé-Peterkin M, Evans H, et al., 2022, Update—Canadian Urological Association Guideline: Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia. Canadian Urological Association Journal, 16(8): 245–256.
Madersbacher S, Klingler H, Djavan B, et al., 1997, Is Obstruction Predictable by Clinical Evaluation in Patients with Lower Urinary Tract Symptoms? British Journal of Urology, 80(1): 72–77.
Dobrek L, 2023, Lower Urinary Tract Disorders as Adverse Drug Reactions—A Literature Review. Pharmaceuticals, 16(7): 1031.
O’Mahony C, Arshad M, Norton S, 2025, Testosterone and Lower Urinary Tract Symptoms: A Narrative Review. Current Urology Reports, 26(1): 75.
Jennings R, Ganote C, Reimer K, 1975, Ischemic Tissue Injury. American Journal of Pathology, 81(1): 179–198.
Ren J, Li Y, Zhang X, et al., 2024, Correlation Between Metabolic Syndrome and Periurethral Prostatic Fibrosis: Results of a Prospective Study. BMC Urology, 24(1): 38.
Kaltsas A, Kratiras Z, Zachariou A, et al., 2024, Evaluating the Impact of Benign Prostatic Hyperplasia Surgical Treatments on Sexual Health. Biomedicines, 12(1): 110.
Kassabian V, 2003, Sexual Function in Patients Treated for Benign Prostatic Hyperplasia. The Lancet, 361(9351): 60–62.
Nollen J, Pijnappel L, Schoones J, et al., 2023, Impact of Early Postoperative Indwelling Urinary Catheter Removal: A Systematic Review. Journal of Clinical Nursing, 32(9–10): 2155–2177.
Abdelmoteleb H, Jefferies E, Drake M, 2016, Assessment and Management of Male Lower Urinary Tract Symptoms (LUTS). International Journal of Surgery, 25: 164–171.
Cash H, Wendler J, Minore A, et al., 2024, Primary Bladder Neck Obstruction in Men—New Perspectives in Physiopathology. Prostate Cancer and Prostatic Diseases, 27(1): 54–57.
Gerard S, Sinclair A, Morley J, et al., 2022, Prostate Diseases. Pathy’s Principles and Practice of Geriatric Medicine, 2: 1136–1152.
Smith C, Chancellor M, 2004, Emerging Role of Botulinum Toxin in the Management of Voiding Dysfunction. Journal of Urology, 171(6): 2128–2137.
Chimenti I, Sattler S, Del Monte-Nieto G, et al., 2022, Editorial: Fibrosis and Inflammation in Tissue Pathophysiology. Frontiers in Physiology, 12: 830683.
Lerner L B, McVary K, Barry M, et al., 2021, Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Part II—Surgical Evaluation and Treatment. Journal of Urology, 206: 818–826.
Nitti V, 2005, Pressure Flow Urodynamic Studies: The Gold Standard for Diagnosing Bladder Outlet Obstruction. Reviews in Urology, 7(Suppl 6): S14–S21.
Blanker M, Brandenbarg P, Slijkhuis B, et al., 2019, Development of an Online Personalized Self-Management Intervention for Men With Uncomplicated LUTS. Neurourology and Urodynamics, 38(6): 1685–1691.